search
Back to results

Non-Invasive Electrical and Magnetic Neuromodulation in Persons With Chronic Spinal (RISES-T2)

Primary Purpose

Spinal Cord Injuries, Spinal Cord Diseases

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
RISES-T System
Sponsored by
Thomas Jefferson University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Spinal Cord Injuries focused on measuring Spinal Cord Injuries, Spinal Electrical Stimulation, Transcutaneous Spinal Stimulation, Transcutaneous Magnetic Simulation, Transcranial Magnetic Stimulation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Has a non-progressive or central cord spinal cord injury American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D Can participate in physical and occupational therapy rehabilitation programs Is at minimum 12 months post-injury Can provide informed consent Has adequate caregiver support to facilitate participation in study Is willing to undergo audio-visual recording sessions - Exclusion Criteria: Has uncontrolled cardiopulmonary disease or cardiac symptoms (as determined by investigators) Has any unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations like severe neuropathic pain, depression, mood disorders or other cognitive disorders Has autonomic dysreflexia that is severe, unstable, and uncontrolled or uncontrolled orthostatic hypotension that may interfere with rehabilitation. Requires ventilator support Has an autoimmune etiology of spinal cord dysfunction/injury Has spasms that limit the ability to participate in the study training (as determined by the Investigator) Has skin breakdown in area(s) that will come into contact with electrodes Has any active implanted medical device (e.g., cochlear implant, pacemaker, neurostimulator or medication infusion device) Is pregnant, planning to become pregnant or currently breastfeeding Has concurrent participation in another drug or device trial that may interfere with this study Has other traumatic injuries such as peripheral nerve injuries, severe musculoskeletal injuries (e.g., shattered pelvis, long bone fractures), that prevent evaluation of response to or participation in rehabilitation. Is not a candidate for other reason determined by the investigators -

Sites / Locations

  • Thomas Jefferson University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Experimental Treatment Arm

Arm Description

Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing repetitive task practice

Outcomes

Primary Outcome Measures

Spinal Cord Injury-Motor Index (SCI MovIN)
evaluates movement, and recovery of neurotypical movement, within a functional context that accounts for compensations and disallows substitutions
Modified Ashworth Scale (MAS)
measures spasticity in patients with lesions to the central nervous system. MAS is an assessment that is used to measure the increase in muscle tone
Manual Muscle Testing (MMT)
standardized set of assessments that measure muscle strength and function

Secondary Outcome Measures

Capabilities of Upper Extremity Test (CUE-T)
A performance measure intended to assess upper extremity function following spinal cord injury (SCI)
PROMIS Pain Interference- Adult Short Form 8a (PROMIS-PI)
A patient self-reported measure of consequences of pain on aspects of their life
Walking Index for SCI (WISCI-II)
A measure of physical assistance needed, as well as devices required, for walking following paralysis that results from SCI
Numeric Pain Rating Scale (NPRS)
The patient reported outcome measure the subjective intensity of pain
Patient Global Impression of Change (PGIC) Questionnaires (bowel program, bladder function, dysreflexia, pain, sensation)
Questionnaires to assess the status of or changes in bladder function, bowel regimen, dysreflexia, pain and sensation.

Full Information

First Posted
July 28, 2023
Last Updated
August 9, 2023
Sponsor
Thomas Jefferson University
Collaborators
Tim Reynolds
search

1. Study Identification

Unique Protocol Identification Number
NCT05994846
Brief Title
Non-Invasive Electrical and Magnetic Neuromodulation in Persons With Chronic Spinal
Acronym
RISES-T2
Official Title
The Reynolds Innovative Spinal Electrical Stimulation Program: Transcutaneous Stimulation (RISES-T 2.0)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
June 23, 2023 (Actual)
Primary Completion Date
June 23, 2025 (Anticipated)
Study Completion Date
June 23, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Thomas Jefferson University
Collaborators
Tim Reynolds

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objectives of this study are to (1) determine the effects of neuromodulation techniques on mobility in persons with chronic SCI, as measured by subjective and objective measures, and (2) to determine the optimal combination of techniques that modify mobility and movement in an individual. The neuromodulation techniques explored will be methods of electromagnetic stimulation - that is, electrical stimulation and magnetic stimulation.
Detailed Description
The study is designed in two Parts. Part 1 of the study will collect information about the participant's baseline mobility and muscular activation potential. The information collected in these sessions will, in effect, assess the participant's eligibility to continue in the study and move onto Part 2. Part 1- Assessment Sessions This part of the study designed to determine (1) which, if any, of the participant's muscles respond to stimulation and, if there are responses observed, (2) what stimulation parameters and modalities would be best suited for the participant during Part 2 of the trial. The team will create a participant-specific menu of modalities and pre-defined parameters for electromagnetic stimulation (e.g., amplitude, channels, frequencies, electrode placement, etc.) from which they will select for participant visits in Part 2 of the study. They will also capture the participant's Movement Signature (the pattern of movement as measured by accelerometers and surface EMG that a person exhibits while sitting/standing at rest and/or doing specific tasks to inform Part 2 of the study. Finally, the participants will complete a Baseline Clinical Outcome Measures validated for SCI to provide baseline data prior to the neuromodulation intervention. Part 2 - The Experimental Cycles This part of the study will consist of Intervention Sessions, in which the team will apply transcutaneous stimulation to the participant's target muscles identified in Part 1, using the parameters and modalities deemed best suited for the participant. during tasks and activities deemed most appropriate for the targeted muscles. The team will measure the effects of electromagnetic stimulation on the participant's muscle activity and movement. The Cycle will also include Biometric sessions, where the participant will engage in a series of upper extremity, trunk and/or lower extremity repetitive tasks from their prescribed "activity library" that was created for them during Part 1 of the study and the team will measure changes in muscle tone, strength, and movement before and after stimulation. In other sessions, the participant will undergo a series of more targeted tasks with and without electromagnetic stimulation applied, to measure changes in the participant's neurophysiology, kinetics, and kinematics due to electromagnetic stimulation. After a series of Intervention and Biometrics Sessions, if there are no changes observed in the participant's kinematics or EMG signals in the and/or in select outcome measures, the participant will enter a Parameter Optimization Session. During this session, the study team will revisit the library of stimulation parameters that were defined for the participant during Part 1 of the study and refine the parameters for use in the next Experimental Cycle. The manipulation and refinement of these parameters will be done with the aim of achieving changes in the subsequent Experimental Cycle. The participant will continue in the study until the time that there is no observed effect of stimulation for three (3) consecutive Experimental Cycles, or may continue for a maximum of six (6) Experimental Cycles. At the end of the study, the participant will repeat the series of Clinical Outcome Measures that were completed at Baseline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries, Spinal Cord Diseases
Keywords
Spinal Cord Injuries, Spinal Electrical Stimulation, Transcutaneous Spinal Stimulation, Transcutaneous Magnetic Simulation, Transcranial Magnetic Stimulation

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective, unblinded, feasibility study where participants will serve as their own controls.
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Treatment Arm
Arm Type
Experimental
Arm Description
Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing repetitive task practice
Intervention Type
Device
Intervention Name(s)
RISES-T System
Other Intervention Name(s)
Trancutaneous spinal stimulation
Intervention Description
The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
Primary Outcome Measure Information:
Title
Spinal Cord Injury-Motor Index (SCI MovIN)
Description
evaluates movement, and recovery of neurotypical movement, within a functional context that accounts for compensations and disallows substitutions
Time Frame
Starting 4 weeks after consent, 3 times every 2 weeks for up to 22 weeks
Title
Modified Ashworth Scale (MAS)
Description
measures spasticity in patients with lesions to the central nervous system. MAS is an assessment that is used to measure the increase in muscle tone
Time Frame
Starting 4 weeks after consent, 3 times every 2 weeks for up to 22 weeks
Title
Manual Muscle Testing (MMT)
Description
standardized set of assessments that measure muscle strength and function
Time Frame
Starting 4 weeks after consent, 3 times every 2 weeks for up to 22 weeks
Secondary Outcome Measure Information:
Title
Capabilities of Upper Extremity Test (CUE-T)
Description
A performance measure intended to assess upper extremity function following spinal cord injury (SCI)
Time Frame
Once at 2 weeks after consent, and once within 9-24 weeks after consent
Title
PROMIS Pain Interference- Adult Short Form 8a (PROMIS-PI)
Description
A patient self-reported measure of consequences of pain on aspects of their life
Time Frame
Once at 2 weeks after consent, and once within 9-24 weeks after consent
Title
Walking Index for SCI (WISCI-II)
Description
A measure of physical assistance needed, as well as devices required, for walking following paralysis that results from SCI
Time Frame
Once at 2 weeks after consent, and once within 9-24 weeks after consent
Title
Numeric Pain Rating Scale (NPRS)
Description
The patient reported outcome measure the subjective intensity of pain
Time Frame
Once at 2 weeks after consent, and once within 9-24 weeks after consent
Title
Patient Global Impression of Change (PGIC) Questionnaires (bowel program, bladder function, dysreflexia, pain, sensation)
Description
Questionnaires to assess the status of or changes in bladder function, bowel regimen, dysreflexia, pain and sensation.
Time Frame
Once at 2 weeks after consent, and once within 9-24 weeks after consent

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has a non-progressive or central cord spinal cord injury American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D Can participate in physical and occupational therapy rehabilitation programs Is at minimum 12 months post-injury Can provide informed consent Has adequate caregiver support to facilitate participation in study Is willing to undergo audio-visual recording sessions - Exclusion Criteria: Has uncontrolled cardiopulmonary disease or cardiac symptoms (as determined by investigators) Has any unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations like severe neuropathic pain, depression, mood disorders or other cognitive disorders Has autonomic dysreflexia that is severe, unstable, and uncontrolled or uncontrolled orthostatic hypotension that may interfere with rehabilitation. Requires ventilator support Has an autoimmune etiology of spinal cord dysfunction/injury Has spasms that limit the ability to participate in the study training (as determined by the Investigator) Has skin breakdown in area(s) that will come into contact with electrodes Has any active implanted medical device (e.g., cochlear implant, pacemaker, neurostimulator or medication infusion device) Is pregnant, planning to become pregnant or currently breastfeeding Has concurrent participation in another drug or device trial that may interfere with this study Has other traumatic injuries such as peripheral nerve injuries, severe musculoskeletal injuries (e.g., shattered pelvis, long bone fractures), that prevent evaluation of response to or participation in rehabilitation. Is not a candidate for other reason determined by the investigators -
Facility Information:
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26205686
Citation
Gerasimenko Y, Gorodnichev R, Moshonkina T, Sayenko D, Gad P, Reggie Edgerton V. Transcutaneous electrical spinal-cord stimulation in humans. Ann Phys Rehabil Med. 2015 Sep;58(4):225-231. doi: 10.1016/j.rehab.2015.05.003. Epub 2015 Jul 20.
Results Reference
background
PubMed Identifier
36212800
Citation
Manson G, Atkinson DA, Shi Z, Sheynin J, Karmonik C, Markley RL, Sayenko DG. Transcutaneous spinal stimulation alters cortical and subcortical activation patterns during mimicked-standing: A proof-of-concept fMRI study. Neuroimage Rep. 2022 Jun;2(2):100090. doi: 10.1016/j.ynirp.2022.100090. Epub 2022 Mar 8.
Results Reference
background
PubMed Identifier
34362062
Citation
Kumru H, Rodriguez-Canon M, Edgerton VR, Garcia L, Flores A, Soriano I, Opisso E, Gerasimenko Y, Navarro X, Garcia-Alias G, Vidal J. Transcutaneous Electrical Neuromodulation of the Cervical Spinal Cord Depends Both on the Stimulation Intensity and the Degree of Voluntary Activity for Training. A Pilot Study. J Clin Med. 2021 Jul 25;10(15):3278. doi: 10.3390/jcm10153278.
Results Reference
background
PubMed Identifier
33192348
Citation
Rejc E, Smith AC, Weber KA 2nd, Ugiliweneza B, Bert RJ, Negahdar M, Boakye M, Harkema SJ, Angeli CA. Spinal Cord Imaging Markers and Recovery of Volitional Leg Movement With Spinal Cord Epidural Stimulation in Individuals With Clinically Motor Complete Spinal Cord Injury. Front Syst Neurosci. 2020 Oct 21;14:559313. doi: 10.3389/fnsys.2020.559313. eCollection 2020.
Results Reference
background
PubMed Identifier
35160091
Citation
Barss TS, Parhizi B, Porter J, Mushahwar VK. Neural Substrates of Transcutaneous Spinal Cord Stimulation: Neuromodulation across Multiple Segments of the Spinal Cord. J Clin Med. 2022 Jan 27;11(3):639. doi: 10.3390/jcm11030639.
Results Reference
background
PubMed Identifier
30190556
Citation
Capogrosso M, Wagner FB, Gandar J, Moraud EM, Wenger N, Milekovic T, Shkorbatova P, Pavlova N, Musienko P, Bezard E, Bloch J, Courtine G. Configuration of electrical spinal cord stimulation through real-time processing of gait kinematics. Nat Protoc. 2018 Sep;13(9):2031-2061. doi: 10.1038/s41596-018-0030-9.
Results Reference
background
PubMed Identifier
26779815
Citation
Wenger N, Moraud EM, Gandar J, Musienko P, Capogrosso M, Baud L, Le Goff CG, Barraud Q, Pavlova N, Dominici N, Minev IR, Asboth L, Hirsch A, Duis S, Kreider J, Mortera A, Haverbeck O, Kraus S, Schmitz F, DiGiovanna J, van den Brand R, Bloch J, Detemple P, Lacour SP, Bezard E, Micera S, Courtine G. Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury. Nat Med. 2016 Feb;22(2):138-45. doi: 10.1038/nm.4025. Epub 2016 Jan 18.
Results Reference
background
PubMed Identifier
21435574
Citation
Najib U, Bashir S, Edwards D, Rotenberg A, Pascual-Leone A. Transcranial brain stimulation: clinical applications and future directions. Neurosurg Clin N Am. 2011 Apr;22(2):233-51, ix. doi: 10.1016/j.nec.2011.01.002.
Results Reference
background
PubMed Identifier
21842407
Citation
Pascual-Leone A, Freitas C, Oberman L, Horvath JC, Halko M, Eldaief M, Bashir S, Vernet M, Shafi M, Westover B, Vahabzadeh-Hagh AM, Rotenberg A. Characterizing brain cortical plasticity and network dynamics across the age-span in health and disease with TMS-EEG and TMS-fMRI. Brain Topogr. 2011 Oct;24(3-4):302-15. doi: 10.1007/s10548-011-0196-8. Epub 2011 Aug 14.
Results Reference
background
PubMed Identifier
19833552
Citation
Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14.
Results Reference
background

Learn more about this trial

Non-Invasive Electrical and Magnetic Neuromodulation in Persons With Chronic Spinal

We'll reach out to this number within 24 hrs